Blase C. Billack
Billack, B. C. (2014). Selected ebselen analogs reduce mechlorethamine toxicity in vitro.. Cutaneous and Ocular Toxicology.
Billack, B. C. (2014). Use of the mouse ear vesicant model to evaluate the effectiveness of ebselen as a countermeasure to the nitrogen mustard mechlorethamine. . Journal of Applied Toxicology.
Billack, B. C. (2013). Ebselen reduces the toxicity of mechlorethamine in A-431 cells via inhibition of apoptosis.. Journal of Biochemical and Molecular Toxicology.
Billack, B. C. (2013). Selected ebselen analogues reduce 2-chloroethyl ethyl sulphide (CEES) Toxicity in A-431 Cells.. Archives of Industrial Hygiene and Toxicology.
Billack, B. C. (2010). BRCA1 protein and nucleolin colocalize in breast carcinoma tissue and cancer cell lines. . American Journal of Pathology.
Billack, B. C. (2009). Analysis of missense, frameshift, and splicing variants of BRCA1. . Mutation Research: Fundamental and Molecular Mechanisms of Mutagenesis.
Billack, B. C. (2008). Reduction of vesicant toxicity by butylated hydroxyanisole.. Cutaneous and Ocular Toxicology.
Billack, B. C. (2007). Ebselen protects brain, skin, lung and blood cells from mechloroethamine toxicity. . Toxicology and Industrial Health.
Billack, B. C. (2005). BRCA1 in breast and ovarian cancer predisposition. Cancer Letters.
Billack, B. C. (2004). Methods to classify BRCA1 variants of uncertain clinical significance. . Cancer Biology and Therapy.
Billack, B. C. (2002). A naturally- occurring allele of BRCA1 encoding for a temperature-sensitive mutant protein.. Cancer Biology and Therapy.
Billack, B. C. (2002). Mutations in the BRCT domain confer temperature-sensitivity to BRCA1 in transcription activation.. Cancer Biology and Therapy.
Billack, B. C. (2012). Potential Tumor Biomarkers for Ovarian Cancer. In: Ovarian Cancer - Basic Science Perspective. InTech..